Endovascular Therapy Beats tPA Alone for Stroke Patients
(HealthDay News) — Endovascular therapy with mechanical thrombectomy in ischemic stroke is superior to standard treatment with tissue plasminogen activator (tPA) for preserving brain function, according to research published in the Nov. 3 issue of the Journal of the American Medical Association.
Saleh Almenawer, M.D., a neurosurgeon at McMaster University in Hamilton, Canada, and colleagues combined data from eight trials involving 2,423 stroke patients, including 1,313 who underwent endovascular therapy with mechanical thrombectomy and 1,110 who received standard medical care with tPA.
The researchers found that 44.6 percent of patients who underwent endovascular therapy with mechanical thrombectomy experienced functional independence at 90 days, compared with 31.8 percent of patients treated with tPA. There were no significant differences in rates of symptomatic intracranial hemorrhage within 90 days or all-cause mortality at 90 days between the two groups.
Stroke patients appeared to have the best outcomes if doctors used an angiogram to locate the clot, if the latest device was used, and if patients were given tPA before clot removal, Almenawer told HealthDay. "The combination therapy is perhaps the way to go," he said. "When stroke patients arrive to the hospital, the protocol should be followed. The intravenous tPA should be administered and the angiogram should be performed to locate the blockage."